[96a5a0]: / output / allTrials / logical / NCT01967160_logical.json

Download this file

389 lines (389 with data), 18.8 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
{
"info": {
"nct_id": "NCT01967160",
"official_title": "A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway",
"inclusion_criteria": "* ≥ 18 years old\n* diagnosed with cancer\n* subsequent to cancer diagnosis, initiating cancer-related antiresorptive treatment during the treatment cohort identification period with XGEVA or zoledronic acid or switching to XGEVA from cancer-related treatment with oral or IV bisphosphonates at the dose indicated for SRE prevention of less than 2 years duration (≤ 24 IV infusions or ≤ 24 monthly oral prescriptions)\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
"exclusion_criteria": "* history of radiation treatment for head and neck cancer before a subject's potential index date\n* hypercalcemia of malignancy as the sole indication for treatment with an anti-resorptive agent",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* ≥ 18 years old",
"criterions": [
{
"exact_snippets": "≥ 18 years old",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "≥ 18 years old",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
}
},
{
"identified_line": {
"line": "* diagnosed with cancer",
"criterions": [
{
"exact_snippets": "diagnosed with cancer",
"criterion": "cancer diagnosis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "diagnosed with cancer",
"criterion": "cancer diagnosis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* subsequent to cancer diagnosis, initiating cancer-related antiresorptive treatment during the treatment cohort identification period with XGEVA or zoledronic acid or switching to XGEVA from cancer-related treatment with oral or IV bisphosphonates at the dose indicated for SRE prevention of less than 2 years duration (≤ 24 IV infusions or ≤ 24 monthly oral prescriptions)",
"criterions": [
{
"exact_snippets": "subsequent to cancer diagnosis",
"criterion": "cancer diagnosis",
"requirement": {
"requirement_type": "timing",
"expected_value": "subsequent"
}
},
{
"exact_snippets": "initiating cancer-related antiresorptive treatment during the treatment cohort identification period with XGEVA or zoledronic acid",
"criterion": "cancer-related antiresorptive treatment",
"requirement": {
"requirement_type": "initiation",
"expected_value": true
}
},
{
"exact_snippets": "initiating cancer-related antiresorptive treatment during the treatment cohort identification period with XGEVA or zoledronic acid",
"criterion": "cancer-related antiresorptive treatment",
"requirement": {
"requirement_type": "medication",
"expected_value": [
"XGEVA",
"zoledronic acid"
]
}
},
{
"exact_snippets": "switching to XGEVA from cancer-related treatment with oral or IV bisphosphonates",
"criterion": "switching to XGEVA",
"requirement": {
"requirement_type": "previous treatment",
"expected_value": [
"oral bisphosphonates",
"IV bisphosphonates"
]
}
},
{
"exact_snippets": "at the dose indicated for SRE prevention of less than 2 years duration (≤ 24 IV infusions or ≤ 24 monthly oral prescriptions)",
"criterion": "SRE prevention dose duration",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 24,
"unit": "IV infusions"
},
{
"operator": "<=",
"value": 24,
"unit": "monthly oral prescriptions"
}
]
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "subsequent to cancer diagnosis",
"criterion": "cancer diagnosis",
"requirement": {
"requirement_type": "timing",
"expected_value": "subsequent"
}
},
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "initiating cancer-related antiresorptive treatment during the treatment cohort identification period with XGEVA or zoledronic acid",
"criterion": "cancer-related antiresorptive treatment",
"requirement": {
"requirement_type": "initiation",
"expected_value": true
}
},
{
"exact_snippets": "initiating cancer-related antiresorptive treatment during the treatment cohort identification period with XGEVA or zoledronic acid",
"criterion": "cancer-related antiresorptive treatment",
"requirement": {
"requirement_type": "medication",
"expected_value": [
"XGEVA",
"zoledronic acid"
]
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "switching to XGEVA from cancer-related treatment with oral or IV bisphosphonates",
"criterion": "switching to XGEVA",
"requirement": {
"requirement_type": "previous treatment",
"expected_value": [
"oral bisphosphonates",
"IV bisphosphonates"
]
}
},
{
"exact_snippets": "at the dose indicated for SRE prevention of less than 2 years duration (≤ 24 IV infusions or ≤ 24 monthly oral prescriptions)",
"criterion": "SRE prevention dose duration",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 24,
"unit": "IV infusions"
},
{
"operator": "<=",
"value": 24,
"unit": "monthly oral prescriptions"
}
]
}
}
}
]
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
},
{
"identified_line": {
"line": "Must have maximum age of 99 Years",
"criterions": [
{
"exact_snippets": "maximum age of 99 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 99,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "maximum age of 99 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 99,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* history of radiation treatment for head and neck cancer before a subject's potential index date",
"criterions": [
{
"exact_snippets": "history of radiation treatment for head and neck cancer",
"criterion": "radiation treatment history",
"requirement": {
"requirement_type": "condition",
"expected_value": "head and neck cancer"
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "history of radiation treatment for head and neck cancer",
"criterion": "radiation treatment history",
"requirement": {
"requirement_type": "condition",
"expected_value": "head and neck cancer"
}
}
}
},
{
"identified_line": {
"line": "* hypercalcemia of malignancy as the sole indication for treatment with an anti-resorptive agent",
"criterions": [
{
"exact_snippets": "hypercalcemia of malignancy",
"criterion": "hypercalcemia of malignancy",
"requirement": {
"requirement_type": "indication for treatment",
"expected_value": "sole"
}
},
{
"exact_snippets": "treatment with an anti-resorptive agent",
"criterion": "treatment with an anti-resorptive agent",
"requirement": {
"requirement_type": "indication",
"expected_value": "hypercalcemia of malignancy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "hypercalcemia of malignancy",
"criterion": "hypercalcemia of malignancy",
"requirement": {
"requirement_type": "indication for treatment",
"expected_value": "sole"
}
},
{
"exact_snippets": "treatment with an anti-resorptive agent",
"criterion": "treatment with an anti-resorptive agent",
"requirement": {
"requirement_type": "indication",
"expected_value": "hypercalcemia of malignancy"
}
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}